title: Site-directed delivery of VEGF-targeted liposomes into intracranial C6 glioma.
abstract: The efficiency of conventional chemotherapy for aggressive tumors in the CNS remains low and new strategies for the targeted delivery of anti-tumor substances are now actively developed. Pegylated liposomes covalently conjugated with monoclonal antibodies to VEGF synthesized by us are nanoparticle characterized by narrow size distribution and high dispersion stability. Immunochemical activity of antibodies after conjugation was 70% of initial level. The anti-VEGF liposomes developed by us were highly specific for VEGF(+) tumor cells (in vitro and in vivo). Intravenous injection of VEGF-liposomes to rats with intracranial C6 glioma was followed by their specific accumulation in the malignant tissues and engulfment by glioma cells, which attested to target delivery and selective accumulation of anti-VEGF-liposomes in the brain tumor. Thus, the use of targeting molecules can significantly increase the distribution and efficiency of delivery of nanocontainers to a tumor characterized by hyperexpression of the target proteins.
authors.affiliation: Department of Fundamental and Applied Neurobiology, V. P. Serbsky State Scientific Center of Social and Forensic Psychiatry, Ministry of Health of the Russian Federation, Moscow, Russia, sheinsergey@gmail.com.
authors.forename: S A
authors.initials: SA
authors.lastname: Shein
authors.forename: N V
authors.initials: NV
authors.lastname: Nukolova
authors.forename: A A
authors.initials: AA
authors.lastname: Korchagina
authors.forename: T O
authors.initials: TO
authors.lastname: Abakumova
authors.forename: I I
authors.initials: II
authors.lastname: Kiuznetsov
authors.forename: M A
authors.initials: MA
authors.lastname: Abakumov
authors.forename: V P
authors.initials: VP
authors.lastname: Baklaushev
authors.forename: O I
authors.initials: OI
authors.lastname: Gurina
authors.forename: V P
authors.initials: VP
authors.lastname: Chekhonin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D008081:Liposomes / Q000008:administration & dosage* / Q000737:chemistry*; D051381:Rats; D017208:Rats, Wistar; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D008081:Liposomes; D042461:Vascular Endothelial Growth Factor A